Getty Images
According to a recent BBC article, researchers from Moderna and MSD have successfully completed a phase-IIb randomized clinical trial for a personalized cancer vaccine. The vaccine uses messenger-RNA technology, similar to the Covid-19 vaccine, and is designed to prime the immune system to attack cancer cells. In the trial of 157 patients taking Keytruda for advanced melanoma, the vaccine was found to reduce the risk of death or cancer progression by 44%. The vaccine is highly personalized, tailored to match each patient's cancer, and is very expensive to make, but it is a significant development in the field of cancer treatment.
